Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CBX7 | O95931 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753283 | 0.90 | RAB9A (0.85) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL12566040 | 0.90 | ALDH1A1 (0.61) | RAB9ANPC1L3MBTL1MAPTCYP2C9 | |
| SCHEMBL6204395 | 0.85 | RAB9A (0.74) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL9262872 | 0.85 | RAB9A (0.74) | RAB9ANPC1L3MBTL1MAPTCYP2C9 | |
| SCHEMBL6199337 | 0.85 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL6224695 | 0.85 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL25244126 | 0.84 | NPC1 (0.68) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL9788856 | 0.84 | NPC1 (0.68) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL10649146 | 0.83 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTCYP2C19 | |
| SCHEMBL1393818 | 0.83 | L3MBTL1 (0.76) | RAB9ANPC1L3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| EP-1633354-B1 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | INST FOR PHARM DISCOVERY INC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1633354-B1 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | INST FOR PHARM DISCOVERY INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633354-A2 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004092146-A2 | N- (((((1,3-THIAZOL-2-YL) AMINO) CARBONYL) PHENYL) SULFONYL) PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | RAB9A 124/4885NPC1 3616/4885L3MBTL1 1475/4885 |
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | PTP4A1, PTPRJ, PPM1B | RAB9A 2316/4885NPC1 720/4885L3MBTL1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.